Physician profile
Larry Bans
NPI 1407820517
$5,219.68
in general payments reported to CMS, 2019-2025
23 companies · $3,408 in 2025
The $3,408 reported for 2025 was more than what 88% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $216 · 2021: $163 · 2022: $406 · 2023: $184 · 2024: $279 · 2025: $3,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,267 · Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,266.89 |
| Food and Beverage | $1,605.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $3,052.95 | 2025 | Nanoknife |
| Pfizer INC. | $407.12 | 2019-2023 | |
| Progenics Pharmaceuticals, INC. | $349.90 | 2023-2025 | Pylarify |
| Janssen Biotech, INC. | $214.96 | 2019-2024 | Erleada |
| Blue Earth Diagnostics | $173.77 | 2021-2025 | Posluma |
| Genzyme Corporation | $172.55 | 2021-2022 | |
| Tempus Ai, INC | $110.73 | 2024-2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $108.78 | 2020-2021 | |
| Profound Medical Corp. | $106.18 | 2021-2022 | |
| Astellas Pharma US INC | $83.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $74.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $51.71 | 2025 | |
| Menarini Silicon Biosystems, INC. | $49.58 | 2024 | |
| Dendreon Pharmaceuticals LLC | $47.36 | 2019-2023 | Provenge |
| Myriad Genetic Laboratories, INC. | $34.98 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Varian Medical Systems, INC. | $29.14 | 2019 | |
| Novocure INC. | $28.19 | 2025 | Optune Lua (Novottf-200t) |
| Sun Pharmaceutical Industries INC. | $26.73 | 2020 | |
| Abbvie INC. | $24.18 | 2023 | Lupron Depot |
| Eisai INC. | $23.52 | 2024 | |
| Ferring Pharmaceuticals INC. | $21.25 | 2024 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $15.78 | 2024 | |
| Foundation Medicine, INC. | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Bans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.